1. Home
  2. USNA vs OMER Comparison

USNA vs OMER Comparison

Compare USNA & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo USANA Health Sciences Inc.

USNA

USANA Health Sciences Inc.

HOLD

Current Price

$12.86

Market Cap

397.1M

Sector

Health Care

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$17.28

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USNA
OMER
Founded
1992
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.1M
844.6M
IPO Year
1996
2008

Fundamental Metrics

Financial Performance
Metric
USNA
OMER
Price
$12.86
$17.28
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
185.8K
2.2M
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.15
EPS
N/A
0.77
Revenue
$1,060,902,000.00
$29,868,000.00
Revenue This Year
$3.90
N/A
Revenue Next Year
$6.21
$233.22
P/E Ratio
N/A
$22.32
Revenue Growth
N/A
N/A
52 Week Low
$13.31
$3.94
52 Week High
$32.32
$18.14

Technical Indicators

Market Signals
Indicator
USNA
OMER
Relative Strength Index (RSI) 24.14 81.28
Support Level N/A $9.12
Resistance Level $20.57 $17.65
Average True Range (ATR) 0.96 0.74
MACD -0.78 0.53
Stochastic Oscillator 0.10 84.06

Price Performance

Historical Comparison
USNA
OMER

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: